Ligand Pharmaceuticals LGND Available-for-Sale Debt Securities - Single Maturity Date

Available-for-Sale Debt Securities - Single Maturity Date at other companies

KKR & Co.KKR

$54.04B+10.1%

The Travelers CompaniesTRV

$76.6B+7.8%

Provident Financial ServicesPFS

$2.87B+15.2%

Corebridge FinancialCRBG

$57.75B+2.5%

International BancsharesIBOC

$4.84B-0.8%

Qualys, Inc.QLYS

$191.88M+27.7%

Other financials

Income statement

See full

Revenue$51.7M+14.1%

Operating income$17.4M+148%

Net income-$13.3M+68.6%

EPS (diluted)-$0.67+69.7%

Balance sheet

See full

Cash & equivalents$115.1M+140%

Total debt$5.1M+14.2%

Total equity$997.3M+25.4%

Total assets$1.5B+69.2%

Cash flow

See full

Operating cash flow$48.7M+291%

CapEx$228.0K+6.5%

Free cash flow$48.5M+289%

Valuation

See full

Market cap$5.6B+96.7%

Profitability

See full

Gross margin91.9%—

Operating margin34.5%+23.0pp

Net margin55.9%+35.7pp

FCF margin44.8%+16.8pp

Returns & leverage

See full

Return on equity17.1%+11.5pp

Debt / equity0×0.0×

Current ratio21.3×+16.0×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate.

The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ligand Pharmaceuticals's available-for-sale debt securities - single maturity date.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ligand Pharmaceuticals's available-for-sale debt securities - single maturity date?: Ligand Pharmaceuticals (LGND) reported available-for-sale debt securities - single maturity date of $588.06M in Q1 2026.
How has Ligand Pharmaceuticals's available-for-sale debt securities - single maturity date changed year-over-year?: Ligand Pharmaceuticals's available-for-sale debt securities - single maturity date increased by 353.5% year-over-year, from $129.66M to $588.06M.